Sun Pharmaceutical Industries Limited (SUNPHARMA.BO)
INR 1688.75
(1.22%)
INR 1688.75
(1.22%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 183.56 Billion INR | -14.33% |
| 2022 | 214.28 Billion INR | 14.38% |
| 2021 | 187.33 Billion INR | 3.01% |
| 2020 | 181.86 Billion INR | -4.92% |
| 2019 | 191.27 Billion INR | -4.22% |
| 2018 | 199.71 Billion INR | -10.52% |
| 2017 | 223.18 Billion INR | 6.38% |
| 2016 | 209.79 Billion INR | 13.63% |
| 2015 | 184.62 Billion INR | -4.18% |
| 2014 | 192.67 Billion INR | 115.89% |
| 2013 | 89.24 Billion INR | 125.49% |
| 2012 | 39.57 Billion INR | 28.64% |
| 2011 | 30.76 Billion INR | 50.62% |
| 2010 | 20.42 Billion INR | 94.54% |
| 2009 | 10.49 Billion INR | 2.79% |
| 2008 | 10.21 Billion INR | 13.66% |
| 2007 | 8.98 Billion INR | -40.42% |
| 2006 | 15.08 Billion INR | -35.3% |
| 2005 | 23.31 Billion INR | 7.37% |
| 2004 | 21.71 Billion INR | 210.75% |
| 2003 | 6.98 Billion INR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | - INR | -100.0% |
| 2024 Q2 | 187.36 Billion INR | 0.0% |
| 2023 Q2 | 162.44 Billion INR | 0.0% |
| 2023 Q4 | 183.56 Billion INR | 0.0% |
| 2023 Q3 | - INR | -100.0% |
| 2023 FY | 183.56 Billion INR | -14.33% |
| 2023 Q1 | - INR | -100.0% |
| 2022 FY | 214.28 Billion INR | 14.38% |
| 2022 Q3 | - INR | -100.0% |
| 2022 Q2 | 180.91 Billion INR | 0.0% |
| 2022 Q1 | - INR | -100.0% |
| 2022 Q4 | 214.28 Billion INR | 0.0% |
| 2021 Q4 | 187.33 Billion INR | 0.0% |
| 2021 FY | 187.33 Billion INR | 3.01% |
| 2021 Q1 | - INR | -100.0% |
| 2021 Q2 | 165.92 Billion INR | 0.0% |
| 2021 Q3 | - INR | -100.0% |
| 2020 FY | 181.86 Billion INR | -4.92% |
| 2020 Q4 | 181.86 Billion INR | 0.0% |
| 2020 Q3 | - INR | -100.0% |
| 2020 Q2 | 194.17 Billion INR | 0.0% |
| 2020 Q1 | - INR | -100.0% |
| 2019 Q1 | - INR | -100.0% |
| 2019 FY | 191.27 Billion INR | -4.22% |
| 2019 Q4 | 191.27 Billion INR | 0.0% |
| 2019 Q3 | - INR | -100.0% |
| 2019 Q2 | 181.94 Billion INR | 0.0% |
| 2018 Q3 | - INR | -100.0% |
| 2018 Q1 | - INR | -100.0% |
| 2018 FY | 199.71 Billion INR | -10.52% |
| 2018 Q4 | 199.71 Billion INR | 0.0% |
| 2018 Q2 | 253.36 Billion INR | 0.0% |
| 2017 FY | 223.18 Billion INR | 6.38% |
| 2017 Q4 | 223.18 Billion INR | 0.0% |
| 2017 Q3 | - INR | -100.0% |
| 2017 Q2 | 234.57 Billion INR | 0.0% |
| 2017 Q1 | - INR | -100.0% |
| 2016 Q4 | 209.79 Billion INR | 0.0% |
| 2016 FY | 209.79 Billion INR | 13.63% |
| 2016 Q1 | - INR | -100.0% |
| 2016 Q2 | 200.43 Billion INR | 0.0% |
| 2016 Q3 | - INR | -100.0% |
| 2015 Q3 | - INR | -100.0% |
| 2015 Q2 | 192.83 Billion INR | 0.0% |
| 2015 Q4 | 184.62 Billion INR | 0.0% |
| 2015 Q1 | - INR | -100.0% |
| 2015 FY | 184.62 Billion INR | -4.18% |
| 2014 Q4 | 192.67 Billion INR | 0.0% |
| 2014 Q3 | - INR | -100.0% |
| 2014 Q2 | 72.11 Billion INR | 0.0% |
| 2014 Q1 | - INR | -100.0% |
| 2014 FY | 192.67 Billion INR | 115.89% |
| 2013 FY | 89.24 Billion INR | 125.49% |
| 2013 Q4 | 89.24 Billion INR | 0.0% |
| 2013 Q3 | - INR | -100.0% |
| 2013 Q1 | - INR | -100.0% |
| 2013 Q2 | 70.39 Billion INR | 0.0% |
| 2012 FY | 39.57 Billion INR | 28.64% |
| 2012 Q4 | 39.57 Billion INR | 0.0% |
| 2012 Q2 | 29.7 Billion INR | 0.0% |
| 2011 Q4 | 30.76 Billion INR | 0.0% |
| 2011 FY | 30.76 Billion INR | 50.62% |
| 2010 FY | 20.42 Billion INR | 94.54% |
| 2009 FY | 10.49 Billion INR | 2.79% |
| 2008 FY | 10.21 Billion INR | 13.66% |
| 2007 FY | 8.98 Billion INR | -40.42% |
| 2006 FY | 15.08 Billion INR | -35.3% |
| 2005 FY | 23.31 Billion INR | 7.37% |
| 2004 FY | 21.71 Billion INR | 210.75% |
| 2003 FY | 6.98 Billion INR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 16.27 Billion INR | -1028.004% |
| Aurobindo Pharma Limited | 152.2 Billion INR | -20.605% |
| Glenmark Life Sciences Limited | 5.18 Billion INR | -3443.189% |
| Granules India Limited | 22.95 Billion INR | -699.713% |
| Indoco Remedies Limited | 10.34 Billion INR | -1674.935% |
| Achyut Healthcare Limited | 2.01 Million INR | -9119080.328% |
| Ajanta Pharma Limited | 10.71 Billion INR | -1613.949% |
| Alkem Laboratories Limited | 48.6 Billion INR | -277.675% |
| Alpa Laboratories Limited | 307.12 Million INR | -59670.743% |
| Brooks Laboratories Limited | 248.6 Million INR | -73740.853% |
| AstraZeneca Pharma India Limited | 3.66 Billion INR | -4914.03% |
| Bajaj HealthCare Limited | 4.86 Billion INR | -3671.192% |
| Bliss GVS Pharma Limited | 2.1 Billion INR | -8604.697% |
| Dr. Reddy's Laboratories Limited | 106.96 Billion INR | -71.611% |
| Eris Lifesciences Limited | 38.26 Billion INR | -379.693% |
| FDC Limited | 3.7 Billion INR | -4849.011% |
| Glenmark Pharmaceuticals Limited | 65.11 Billion INR | -181.934% |
| Gufic Biosciences Limited | 5.59 Billion INR | -3178.131% |
| Ind-Swift Laboratories Limited | 2.28 Billion INR | -7918.005% |
| Ipca Laboratories Limited | 33.74 Billion INR | -444.025% |
| Jagsonpal Pharmaceuticals Limited | 296.76 Million INR | -61757.764% |
| Krebs Biochemicals & Industries Limited | 2.97 Billion INR | -6072.643% |
| Lasa Supergenerics Limited | 541.92 Million INR | -33773.525% |
| Laurus Labs Limited | 42.71 Billion INR | -329.757% |
| Lupin Limited | 96.23 Billion INR | -90.746% |
| Mankind Pharma Limited | 23.87 Billion INR | -668.887% |
| Medicamen Biotech Limited | 940.36 Million INR | -19421.006% |
| Medico Remedies Limited | 438.24 Million INR | -41787.419% |
| Megasoft Limited | 1.85 Billion INR | -9805.825% |
| NATCO Pharma Limited | 10.53 Billion INR | -1642.965% |
| Piramal Pharma Limited | 74 Billion INR | -148.052% |
| RPG Life Sciences Limited | 1.38 Billion INR | -13200.181% |
| Sigachi Industries Limited | 2.53 Billion INR | -7152.07% |
| Suven Pharmaceuticals Limited | 2.03 Billion INR | -8924.014% |
| Syncom Formulations (India) Limited | 1.16 Billion INR | -15654.151% |
| Unichem Laboratories Limited | 8.06 Billion INR | -2174.921% |
| Wanbury Limited | 3.15 Billion INR | -5717.402% |
| Windlas Biotech Limited | 1.76 Billion INR | -10314.086% |
| ZIM Laboratories Limited | 2.08 Billion INR | -8722.206% |
| Zydus Lifesciences Limited | 71.79 Billion INR | -155.696% |
| Sun Pharma Advanced Research Company Limited | 3.89 Billion INR | -4615.485% |
| Divi's Laboratories Limited | 18.99 Billion INR | -866.662% |
| Hester Biosciences Limited | 3.59 Billion INR | -5006.631% |
| Procter & Gamble Health Limited | 2.56 Billion INR | -7067.308% |
| Amrutanjan Health Care Limited | 783.82 Million INR | -23319.684% |
| Bal Pharma Limited | 2.51 Billion INR | -7209.794% |
| Strides Pharma Science Limited | 37.68 Billion INR | -387.173% |
| Venus Remedies Limited | 1.39 Billion INR | -13079.861% |
| Aarti Pharmalabs Limited | 8.25 Billion INR | -2124.891% |
| Nectar Lifesciences Limited | 11.21 Billion INR | -1536.368% |
| Shilpa Medicare Limited | 12.93 Billion INR | -1319.443% |
| Aarti Drugs Limited | 11.5 Billion INR | -1495.698% |
| IOL Chemicals and Pharmaceuticals Limited | 6.32 Billion INR | -2800.49% |
| Suven Life Sciences Limited | 148.62 Million INR | -123414.914% |
| Ind-Swift Limited | 13.45 Billion INR | -1264.525% |
| Valiant Laboratories Limited | 1.05 Billion INR | -17246.33% |
| J. B. Chemicals & Pharmaceuticals Limited | 10.7 Billion INR | -1614.317% |
| Solara Active Pharma Sciences Limited | 14.14 Billion INR | -1197.877% |
| Themis Medicare Limited | 1.88 Billion INR | -9625.459% |
| Hikal Limited | 12.99 Billion INR | -1312.624% |
| Torrent Pharmaceuticals Limited | 82.05 Billion INR | -123.728% |
| Sequent Scientific Limited | 8.27 Billion INR | -2118.559% |
| Novartis India Limited | 1.8 Billion INR | -10092.055% |
| Wockhardt Limited | 39.87 Billion INR | -360.419% |
| Jubilant Pharmova Limited | 61.27 Billion INR | -199.587% |
| Biofil Chemicals and Pharmaceuticals Limited | 288.79 Million INR | -63462.928% |
| Neuland Laboratories Limited | 5.49 Billion INR | -3238.493% |
| Morepen Laboratories Limited | 4.45 Billion INR | -4016.094% |
| Kilitch Drugs (India) Limited | 643.88 Million INR | -28409.698% |
| Mangalam Drugs & Organics Limited | 1.97 Billion INR | -9188.472% |